Abstracts tagged "Late-Breaking 2018"

Abstract Number: L12 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Prior Inadequate Response or Intolerance to 1 or 2 Tumor Necrosis Factor Inhibitors
Atul A. Deodhar¹, Denis Poddubnyy², Cesar Pacheco-Tena³, Carlo Salvarani⁴, Eric Lespessailles⁵, Proton Rahman⁶, Pentti Järvinen⁷, Juan Sanchez-Burson⁸, Karl Gaffney⁹, Eun Bong Lee¹⁰, Eswar Krishnan¹¹, Silvia Santisteban¹¹, Xiaoqi Li¹¹, Fangyi Zhao¹¹, Hilde Carlier¹¹ and John D. Reveille¹², ¹Oregon Health & Science University, Portland, Portland, OR, ²Rheumatology, Campus Benjamin Franklin Charité – Universitätsmedizin, Germany and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ³Facultad de Medicina, Universidad Autónoma de Chihuahua, Chihuahua, Mexico, ⁴Azienda USL-IRCCS di Reggio Emilia and Universita’ di Modena e Reggio Emilia, Reggio Emilia, Italy, ⁵Rheumatology, CHR Orléans and University of Orléans, Orléans, France, ⁶Medicine, Memorial University, St John's, NF, Canada, ⁷Rheumatology, Kiljava Medical Research, Hyvinkää, Finland, ⁸Hospital Infanta Luisa, Sevilla, Spain, ⁹Rheumatology, Norfolk and Norwich University Hospital NHS Foundation Trust and Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ¹⁰Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ¹¹Eli Lilly and Company, Indianapolis, IN, ¹²Rheumatology, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX
Background/Purpose: TNF inhibitors (TNFi) are recommended for patients with axial SpA (axSpA) who do not respond to or tolerate NSAIDs. Some patients are inadequate responders…
Abstract Number: L17 • 2018 ACR/ARHP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
Christopher T. Ritchlin¹, Arthur Kavanaugh², Joseph F. Merola³, Georg Schett⁴, Jose U. Scher⁵, Richard B. Warren⁶, Deepak Assudani⁷, Thomas Kumke⁸, Barbara Ink⁷ and Iain B. McInnes⁹, ¹University of Rochester Medical Centre, Rochester, NY, ²UC San Diego School of Medicine, La Jolla, CA, ³Brigham and Women's Hospital Harvard Medical School, Boston, MA, ⁴Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany, ⁵Department of Medicine, NYU Langone Medical Center, New York, NY, ⁶The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹University of Glasgow, Glasgow, United Kingdom
Background/Purpose: IL-17F shares structural homology and overlapping biologic function with IL-17A. In vitro studies demonstrate that IL-17F has biologic effector function that can modulate inflammation.…
Abstract Number: L13 • 2018 ACR/ARHP Annual Meeting
Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial
Xenofon Baraliakos¹, Jürgen Braun², Atul A. Deodhar³, Denis Poddubnyy⁴, Alan J. Kivitz⁵, Hasan Tahir⁶, Filip van Den Bosch⁷, Evie Maria Delicha⁸, Zsolt Talloczy⁹ and Anke Fierlinger⁹, ¹Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, and Ruhr University Bochum, Herne, Germany, Herne, Germany, ³Oregon Health & Science University, Portland, Portland, OR, ⁴Rheumatology, Campus Benjamin Franklin Charité – Universitätsmedizin, Germany and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁵Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁶Whipps Cross University Hospital, Barts Health NHS Trust, London, United Kingdom, ⁷Rheumatology, Universitair Ziekenhuis, Ghent, Belgium, Gent, Belgium, ⁸Novartis Pharma AG, Basel, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States, East Hanover, NJ
Background/Purpose: Clinical evaluation of efficacy and safety for long-term treatment for ankylosing spondylitis (AS) is important for treatment decision-making. Secukinumab (SEC), a fully human mAb…
Abstract Number: L18 • 2018 ACR/ARHP Annual Meeting
A Randomized Controlled 24-Week Trial Evaluating the Safety and Efficacy of Blinded Tapering Versus Continuation of Long-Term Prednisone (5 mg/day) in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab
Gerd R. Burmester¹, Frank Buttgereit¹, Corrado Bernasconi², Jose Maria Alvaro-Gracia³, Nidia Castro², Maxime Dougados⁴, Cem Gabay⁵, Jacob van Laar⁶, J. Michael Nebesky², Attila Pethö-Schramm², Carlo Salvarani⁷, Marc Y. Donath⁸ and Markus R. John², ¹Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Hospital Universitario de La Princesa IIS-IP, Madrid, Spain, ⁴Université Paris-Descartes, Paris, France, ⁵University Hospitals of Geneva, Geneva, Switzerland, ⁶University Medical Centre Utrecht, Utrecht, Netherlands, ⁷Università de Modena e Reggio Emilia, Modena, Italy, ⁸University Hospital Basel, Basel, Switzerland
Background/Purpose: Guidelines recommend low-dose, short-duration glucocorticoid (GC) treatment for RA,1,2 but long-term use, especially at prednisone-equivalent doses >5 mg/d, should be avoided.2 Many patients (pts)…
Abstract Number: L14 • 2018 ACR/ARHP Annual Meeting
Top-Line Results of a Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of a Reversible B Cell Inhibitor, XmAb®5871, in Systemic Lupus Erythematosus (SLE)
Joan T. Merrill¹, Joshua June², Fotios Koumpouras³, Wambui Machua⁴, Mohammad Faisal Khan⁵, Anca Askanase⁶, Arezou Khosroshahi⁷, Saira Sheikh⁸, Paul A. Foster⁹ and Debra J. Zack⁹, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Joshua June, DO, Lansing, MI, ³Internal Medicine, Rheumatology, Yale University School of Medicine, New Haven, CT, ⁴Internal Medicine, Piedmont Atlanta Hospital, Atlanta, GA, ⁵Arthritis & Rheumatology Center of Oklahoma, PLLC, Oklahoma City, OK, ⁶Director, Columbia University Lupus Center, Columbia University Medical Center, Bronx, NY, ⁷Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁸Medicine, University of North Carolina, Chapel Hill, NC, ⁹Xencor, Inc., San Diego, CA
Background/Purpose: XmAb5871 is a humanized anti-CD19 antibody Fc-engineered for increased affinity to FcgRIIb. Co-ligation of CD19 and FcgRIIb inhibits B lineage cells key to SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].